Literature DB >> 22014843

Differences in external price referencing in Europe: a descriptive overview.

Christine Leopold1, Sabine Vogler, A K Mantel-Teeuwisse, Kees de Joncheere, H G M Leufkens, Richard Laing.   

Abstract

OBJECTIVE: This study aimed to provide an up-to-date description as well as comparative analysis of the national characteristics of pharmaceutical external price referencing (EPR) in Europe.
METHODS: Review of the country-specific PPRI (Pharmaceutical Pricing and Reimbursement Information) Pharma Profiles written by representatives of the PPRI Network. The Profiles were analysed according to predefined criteria.
RESULTS: Of 28 analysed European countries 24 applied EPR in 2010. The majority of countries have statutory rules to implement EPR. Most countries had less than 10 countries in their reference baskets. Higher income countries tend to include higher income countries in their basket, whereas lower income countries refer to lower income countries. Taking the average price of all countries in the basket as the basis to calculate the national price was the most common strategy (n=8). The methodology of EPR has changed in most European countries over the past 10 years (n=19).
CONCLUSIONS: EPR is a widely used pricing policy in Europe and is still actively used as well as adjusted by national authorities. However, we still see room for improvement by implementing more detailed legislations in terms of the revision of prices and by identifying alternative countries in case a product is not on the market. We also see the need for formal information sharing (e.g. congresses dedicated to pricing strategies and systems) with other public pricing authorities to learn about the different EPR methodologies as well as the national experiences. These congresses might also give room to better understand national pricing methods including discussions on possible limitations of these pricing methods.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Mesh:

Substances:

Year:  2011        PMID: 22014843     DOI: 10.1016/j.healthpol.2011.09.008

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  26 in total

1.  The definition and role of quality of life in Germany's early assessment of drug benefit: a qualitative approach.

Authors:  David Lohrberg; Matthias Augustin; Christine Blome
Journal:  Qual Life Res       Date:  2015-08-05       Impact factor: 4.147

2.  Use of product listing agreements by Canadian provincial drug benefit plans.

Authors:  Steven G Morgan; Melissa K Friesen; Paige A Thomson; Jamie R Daw
Journal:  Healthc Policy       Date:  2013-05

3.  International impact of external reference pricing: should national policy-makers care?

Authors:  Anna-Maria Fontrier; Jennifer Gill; Panos Kanavos
Journal:  Eur J Health Econ       Date:  2019-07-09

4.  Variations in external reference pricing implementation: does it matter for public policy?

Authors:  Jennifer Gill; Anna-Maria Fontrier; Dionysis Kyriopoulos; Panos Kanavos
Journal:  Eur J Health Econ       Date:  2019-08-23

5.  Reference pricing and price negotiations for innovative new drugs : viable policies in the long term?

Authors:  Afschin Gandjour
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

6.  Linking the Price of Cancer Drug Treatments to Their Clinical Value.

Authors:  Lucia Gozzo; Andrea Navarria; Valentina Drago; Laura Longo; Silvana Mansueto; Giacomo Pignataro; Americo Cicchetti; Salvatore Salomone; Filippo Drago
Journal:  Clin Drug Investig       Date:  2016-07       Impact factor: 2.859

7.  Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data.

Authors:  Christine Blome; Matthias Augustin; Hidayet Metin; David Lohrberg
Journal:  Eur J Health Econ       Date:  2016-02-02

8.  Abstracts from the 3rd International PPRI Conference 2015: Pharmaceutical Pricing and Reimbursement Policies: Challenges Beyond the Financial Crisis.

Authors: 
Journal:  J Pharm Policy Pract       Date:  2015-10-05

9.  Impact of external price referencing on medicine prices - a price comparison among 14 European countries.

Authors:  Christine Leopold; Aukje Katja Mantel-Teeuwisse; Leonhard Seyfang; Sabine Vogler; Kees de Joncheere; Richard Ogilvie Laing; Hubert Leufkens
Journal:  South Med Rev       Date:  2012-12-27

10.  Discounts and rebates granted to public payers for medicines in European countries.

Authors:  Sabine Vogler; Nina Zimmermann; Claudia Habl; Jutta Piessnegger; Anna Bucsics
Journal:  South Med Rev       Date:  2012-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.